AML的治療進展.pptVIP

孙爱宁 教授 主任医师 ;;AML;AML危险分层;;AML现状;2016NCCN新增初诊AML诱导方案： FLAG-Ida Optimization of Chemotherapy for Younger Patients WithAcute Myeloid Leukemia: Results of the Medical ResearchCouncil AML15 Trial;;老年AML患者诱导方案;靶向治疗;;;AML缺乏创新的靶向治疗，目前关于AML的分子靶向制剂必威体育精装版及最有前景的研究主要集中在FLT-3、IDH1、IDH2;FLT-3;FLT3-internal tandem duplications (ITD);;Incidence and progrosic impact of FLT3/ITD mutations in AML subgroups;索拉非尼联合3＋7疗法治疗新诊断为AML的患者的有效性和耐受性 ;;;;Midostaurin;;FLT3抑制剂;IDH1和IDH2;;;靶向治疗的挑战;;;;;; AML在获得第一次缓解后建立完善的风险评估;预后评估;AML患者治疗后的参数，包括MRD以及获得缓解的水平为AML患者独立预后因素;缓解后的治疗选择：化疗or移植 ;;治疗选择;治疗选择;治疗选择;治疗选择;MRD与分子遗传学??后相结合治疗选择;复发/难治AML;复发/难治AML;;移植预处理方案：RIC vs. MAC;预处理方案：RIC vs. MAC;预处理方案：RIC vs. MAC;供体的选择;供体的选择; 供体的选择Haploidentical- versus identical-sibling transplant for AML in remission: a multi-centre,prospective study;供体的选择;analyzed in 161 haploidentical hematopoietic transplants 121 for acute myeloid leukemia (AML) 40 for acute lymphoblastic leukemia (ALL) performed between 1993 and 2012.  69 patients received transplants from NK alloreactive donors 92 patients from non-NK alloreactive donors.;;; 供者年龄The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy;患者年龄; ;另一项来至德国的研究结果同上述EBMT研究结果相似， AZA联合DLI方案的总反应率33％。;小结; 谢谢！